Profile data is unavailable for this security.
About the company
Arjo AB (publ) is a Sweden-based supplier of products, services and solutions for people with reduced mobility and age-related health challenges. The Company’s offering includes products and solutions within the product segments Patient handling, Hygiene, Disinfection, Therapeutic surfaces, Venous Thromboembolism (VTE) prevention and Diagnostics. Additionally, the Company is offering its customers complementing services. The products comprise ceiling lifts, standing and raising aids, slings, floor lifters, among others. Arjo AB (publ) operates in more than 60 countries, which the Company divides into three geographical areas: North America, Western Europe and Rest of the World.
- Revenue in SEK (TTM)11.18bn
- Net income in SEK511.00m
- Incorporated2016
- Employees6.85k
- LocationArjo AB (publ)Hans Michelsensgatan 10MALMO 211 20SwedenSWE
- Websitehttps://www.arjo.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Stille AB | 487.43m | 50.86m | 1.92bn | 151.00 | 33.82 | 2.86 | 25.63 | 3.94 | 6.33 | 6.33 | 60.94 | 74.85 | 0.6978 | 2.10 | 8.49 | 4,598,368.00 | 7.28 | 7.03 | 8.70 | 8.19 | 49.17 | 43.93 | 10.43 | 9.85 | 1.12 | 7.41 | 0.00 | 21.98 | 19.70 | 16.78 | -2.48 | 5.34 | 23.62 | -- |
Detection Technology Oyj | -1.16tn | -1.16tn | 2.38bn | 464.00 | -- | 2.78 | -- | -- | -- | -- | -- | 5.03 | -- | -- | -- | -- | -- | 9.34 | -- | 11.96 | -- | 47.44 | -- | 8.22 | 3.39 | -- | 0.00 | 53.45 | 5.29 | 2.02 | 7.55 | -18.03 | -14.88 | -9.55 |
BICO Group AB | 2.25bn | -786.80m | 2.52bn | 828.00 | -- | 0.874 | -- | 1.12 | -11.15 | -15.20 | 31.92 | 41.79 | 0.3602 | 2.15 | 4.47 | 2,547,964.00 | -12.62 | -- | -14.44 | -- | 55.70 | -- | -35.03 | -- | 2.23 | -0.5705 | 0.397 | -- | 6.09 | -- | -1,889.33 | -- | -- | -- |
Medistim ASA | 538.53m | 100.05m | 2.54bn | 152.00 | 25.32 | 6.35 | 20.34 | 4.71 | 5.55 | 5.55 | 29.87 | 22.12 | 1.13 | 0.7461 | 7.48 | 3,599,204.00 | 21.05 | 22.93 | 25.53 | 28.52 | 79.12 | 78.25 | 18.58 | 20.64 | 2.75 | -- | 0.0181 | 75.25 | 7.00 | 10.06 | -8.91 | 12.72 | 0.033 | 14.87 |
RaySearch Laboratories AB (publ) | 1.17bn | 175.06m | 5.25bn | 414.00 | 38.64 | 8.34 | 12.61 | 4.49 | 5.10 | 5.10 | 34.09 | 23.65 | 0.6023 | 5.51 | 3.29 | 3,005,152.00 | 9.02 | 1.29 | 13.69 | 1.88 | 91.06 | 90.57 | 14.97 | 2.55 | 1.27 | 108.61 | 0.3706 | 69.00 | 21.16 | 10.26 | 243.06 | 0.7648 | -1.31 | -- |
CellaVision AB | 737.16m | 150.21m | 5.78bn | 228.00 | 38.51 | 7.53 | 30.15 | 7.85 | 6.30 | 6.30 | 30.91 | 32.19 | 0.7849 | 1.91 | 7.26 | 3,233,162.00 | 15.99 | 15.30 | 18.45 | 18.24 | 66.99 | 69.03 | 20.38 | 19.98 | 2.15 | 1,358.86 | 0.044 | 110.18 | 5.94 | 13.17 | 10.12 | 8.00 | 30.45 | 8.45 |
Surgical Science Sweden AB | 838.25m | 197.72m | 5.97bn | 265.00 | 30.20 | 1.30 | 23.38 | 7.12 | 3.87 | 3.87 | 16.43 | 90.02 | 0.1695 | 1.49 | 7.35 | 3,224,027.00 | 4.00 | 4.49 | 4.26 | 4.78 | 68.51 | 70.06 | 23.59 | 23.75 | 3.46 | -- | 0.00 | 0.00 | 10.01 | 68.14 | 24.47 | -- | 38.57 | -- |
Arjo AB (publ) | 11.18bn | 511.00m | 8.93bn | 6.85k | 18.72 | 1.22 | 5.96 | 0.7982 | 1.88 | 1.88 | 41.05 | 28.87 | 0.7149 | 4.54 | 6.78 | 1,644,896.00 | 3.26 | 3.55 | 4.62 | 5.55 | 43.64 | 44.01 | 4.56 | 5.41 | 0.626 | 3.97 | 0.4073 | 43.01 | 10.03 | 5.97 | 6.90 | 10.15 | -8.89 | 10.35 |
Revenio Group Oyj | 1.18bn | 220.07m | 9.02bn | 230.00 | 40.53 | 7.67 | 32.12 | 7.63 | 0.7204 | 0.7204 | 3.86 | 3.81 | 0.7834 | 4.93 | 8.17 | 472,574.10 | 14.67 | 14.33 | 17.09 | 17.90 | 49.29 | 50.73 | 18.72 | 21.13 | 1.51 | 34.57 | 0.1276 | 55.81 | -0.4125 | 25.80 | -12.15 | 18.72 | 17.67 | 6.30 |
ChemoMetec A/S | 633.02m | 211.51m | 12.78bn | 173.00 | 60.40 | 14.56 | 53.45 | 20.18 | 7.83 | 7.83 | 23.44 | 32.48 | 0.6112 | 0.745 | 6.97 | 2,357,630.00 | 20.42 | 27.96 | 24.40 | 35.10 | 78.80 | 79.57 | 33.41 | 35.02 | 3.76 | -- | 0.0073 | 144.08 | -8.22 | 18.37 | -23.72 | 26.64 | 9.97 | -11.81 |
Biotage AB | 2.13bn | 257.00m | 12.92bn | 675.00 | 50.29 | 3.39 | 29.50 | 6.07 | 3.21 | 3.21 | 26.56 | 47.60 | 0.4312 | 1.59 | 7.22 | 3,155,786.00 | 5.21 | 10.74 | 6.05 | 12.77 | 62.67 | 61.40 | 12.08 | 15.75 | 1.15 | 43.88 | 0.0616 | 40.11 | 19.54 | 15.50 | -8.21 | 7.97 | 14.05 | 1.30 |
Data as of Nov 13 2024. Currency figures normalised to Arjo AB (publ)'s reporting currency: Swedish Krona SEK
Holder | Shares | % Held |
---|---|---|
Fj�rde AP-fondenas of 30 Apr 2024 | 26.03m | 10.24% |
The Vanguard Group, Inc.as of 30 Apr 2024 | 8.27m | 3.25% |
Svolder AB (Investment Management)as of 30 Apr 2024 | 7.60m | 2.99% |
F�rsta AP-fondenas of 30 Apr 2024 | 6.50m | 2.56% |
Dimensional Fund Advisors LPas of 30 Apr 2024 | 6.28m | 2.47% |
Norges Bank Investment Managementas of 31 Dec 2023 | 5.54m | 2.18% |
Handelsbanken Fonder ABas of 31 Oct 2024 | 4.21m | 1.66% |
BlackRock Fund Advisorsas of 30 Apr 2024 | 3.89m | 1.53% |
SEB Investment Management ABas of 30 Apr 2024 | 3.83m | 1.51% |
E. �hman J :or Fonder ABas of 30 Sep 2024 | 3.75m | 1.48% |
More ▼
Data from 29 Feb 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.